- Home
- KLTR vs TLSI Comparison
KLTR vs TLSI Comparison
Compare KLTR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLTR | TLSI |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.4M | 244.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | KLTR | TLSI |
|---|---|---|
| Price | $1.70 | $7.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.50 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 348.9K | 260.4K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,921,000.00 | $40,207,000.00 |
| Revenue This Year | $3.10 | $55.06 |
| Revenue Next Year | $1.24 | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.88 | ★ 49.52 |
| 52 Week Low | $1.36 | $3.42 |
| 52 Week High | $2.82 | $7.95 |
Technical Indicators
Market Signals| Indicator | KLTR | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 64.32 |
| Support Level | $1.64 | $7.10 |
| Resistance Level | $1.72 | $7.95 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 60.77 | 55.52 |
Price Performance
Historical ComparisonAbout KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.